Adrienne Goode
A5052751755- SARS-CoV-2 and COVID-19 Research
- Immunotherapy and Immune Responses
- COVID-19 Clinical Research Studies
- Viral Infections and Immunology Research
- Vaccine Coverage and Hesitancy
Bioqual
2021-2022
Ad26.COV2.S has demonstrated durability and clinical efficacy against symptomatic COVID-19 in humans. In this study, we report the correlates of humoral cellular immune responses 20 rhesus macaques immunized with single-shot immunogenicity a booster shot at 8 to 10 months after initial immunization. elicited durable binding neutralizing antibodies as well memory B cells long-lived bone marrow plasma cells. Innate cell correlated antibody responses. After boost immunization, multiple...
ABSTRACT mRNA-1273 vaccine efficacy against SARS-CoV-2 Delta wanes over time; however, there are limited data on the impact of durability immune responses protection. We immunized rhesus macaques at weeks 0 and 4 assessed one year in blood, upper lower airways. Serum neutralizing titers to were 280 34 reciprocal ID 50 6 (peak) 48 (challenge), respectively. Antibody binding also decreased bronchoalveolar lavage (BAL). Four days after challenge, virus was unculturable BAL subgenomic RNA...